z230

2026-06-02 17:20:20 +02:00
parent ec187e673a
commit b433ef0446
58 changed files with 9247 additions and 0 deletions
@@ -0,0 +1,10 @@
+{
+  "pk": 3237,
+  "title": "Subject_Number_Creation",
+  "label": "Janssen 77242113UCO3001 Subject CZ100132003 has been created in IRT at site DD5-CZ10013",
+  "event": "Create",
+  "actual_date": "2026-05-06",
+  "subject": "CZ100132003",
+  "study": "77242113UCO3001",
+  "text": "77242113UCO3001\n\nJanssen Pharmaceuticals\nhttps://janssen.4gclinical.com\n\nSubject  CZ100132003  has been created in IRT.\n\nSite Details\n\nLocation: CZE\n\nSite: DD5-CZ10013\n\nInvestigator: David Stepek\n\nSubject Details\n\nSubject: CZ100132003\n\nIRT Subject Status: Screened\n\nRescreened Subject: No\n\nCohort: Adult subjects (18 years or older)\n\nInformed Consent Date at Subject Creation: 06-May-2026\n\n ADT-IR: No\n\n 3 or More Advanced Therapies: No\n\n Ustekinumab: No\n\n Only Oral 5-ASA Compounds: No\n\nDate of Subject Creation in IRT: 06-May-2026\n\nTransaction Date/Time (site local): 06-May-2026 10:33:13\n\nTransaction Date/Time (system local): 06-May-2026 08:33:13\n\nTransaction performed by: dstepek@vnbrno.cz\n\nIf you have questions about this notification, please contact 4G Clinical Support at http://support.4gclinical.com"
+}
@@ -0,0 +1,10 @@
+{
+  "pk": 3510,
+  "title": "Subject_Number_Creation",
+  "label": "Janssen 77242113UCO3001 Subject CZ100032001 has been created in IRT at site DD5-CZ10003",
+  "event": "Create",
+  "actual_date": "2026-05-13",
+  "subject": "CZ100032001",
+  "study": "77242113UCO3001",
+  "text": "77242113UCO3001\n\nJanssen Pharmaceuticals\nhttps://janssen.4gclinical.com\n\nSubject  CZ100032001  has been created in IRT.\n\nSite Details\n\nLocation: CZE\n\nSite: DD5-CZ10003\n\nInvestigator: Leksa Vaclav\n\nSubject Details\n\nSubject: CZ100032001\n\nIRT Subject Status: Screened\n\nRescreened Subject: No\n\nCohort: Adult subjects (18 years or older)\n\nInformed Consent Date at Subject Creation: 13-May-2026\n\n ADT-IR: No\n\n 3 or More Advanced Therapies: No\n\n Ustekinumab: No\n\n Only Oral 5-ASA Compounds: No\n\nDate of Subject Creation in IRT: 13-May-2026\n\nTransaction Date/Time (site local): 13-May-2026 07:44:11\n\nTransaction Date/Time (system local): 13-May-2026 05:44:11\n\nTransaction performed by: vaclav.leksa@seznam.cz\n\nIf you have questions about this notification, please contact 4G Clinical Support at http://support.4gclinical.com"
+}
@@ -0,0 +1,10 @@
+{
+  "pk": 4231,
+  "title": "Subject_Number_Creation",
+  "label": "Janssen 77242113UCO3001 Subject CZ100162002 has been created in IRT at site DD5-CZ10016",
+  "event": "Create",
+  "actual_date": "2026-05-27",
+  "subject": "CZ100162002",
+  "study": "77242113UCO3001",
+  "text": "77242113UCO3001\n\nJanssen Pharmaceuticals\nhttps://janssen.4gclinical.com\n\nSubject  CZ100162002  has been created in IRT.\n\nSite Details\n\nLocation: CZE\n\nSite: DD5-CZ10016\n\nInvestigator: Robert Mudr\n\nSubject Details\n\nSubject: CZ100162002\n\nIRT Subject Status: Screened\n\nRescreened Subject: No\n\nCohort: Adult subjects (18 years or older)\n\nInformed Consent Date at Subject Creation: 27-May-2026\n\n ADT-IR: Yes\n\n 3 or More Advanced Therapies: No\n\n Ustekinumab: No\n\n Only Oral 5-ASA Compounds: No\n\nDate of Subject Creation in IRT: 27-May-2026\n\nTransaction Date/Time (site local): 27-May-2026 11:55:28\n\nTransaction Date/Time (system local): 27-May-2026 09:55:28\n\nTransaction performed by: petr.pekny@nmskb.cz\n\nIf you have questions about this notification, please contact 4G Clinical Support at http://support.4gclinical.com"
+}
@@ -0,0 +1,10 @@
+{
+  "pk": 4271,
+  "title": "Subject_Number_Creation",
+  "label": "Janssen 77242113UCO3001 Subject CZ100012004 has been created in IRT at site DD5-CZ10001",
+  "event": "Create",
+  "actual_date": "2026-05-28",
+  "subject": "CZ100012004",
+  "study": "77242113UCO3001",
+  "text": "77242113UCO3001\n\nJanssen Pharmaceuticals\nhttps://janssen.4gclinical.com\n\nSubject  CZ100012004  has been created in IRT.\n\nSite Details\n\nLocation: CZE\n\nSite: DD5-CZ10001\n\nInvestigator: Matej Falc\n\nSubject Details\n\nSubject: CZ100012004\n\nIRT Subject Status: Screened\n\nRescreened Subject: No\n\nCohort: Adult subjects (18 years or older)\n\nInformed Consent Date at Subject Creation: 28-May-2026\n\n ADT-IR: No\n\n 3 or More Advanced Therapies: No\n\n Ustekinumab: No\n\n Only Oral 5-ASA Compounds: No\n\nDate of Subject Creation in IRT: 28-May-2026\n\nTransaction Date/Time (site local): 28-May-2026 07:14:21\n\nTransaction Date/Time (system local): 28-May-2026 05:14:21\n\nTransaction performed by: matesfalc@seznam.cz\n\nIf you have questions about this notification, please contact 4G Clinical Support at http://support.4gclinical.com"
+}
@@ -0,0 +1,10 @@
+{
+  "pk": 4461,
+  "title": "Randomized",
+  "label": "Janssen 77242113UCO3001 Subject randomized CZ100132003 at site DD5-CZ10013",
+  "event": "I0",
+  "actual_date": "2026-06-02",
+  "subject": "CZ100132003",
+  "study": "77242113UCO3001",
+  "text": "77242113UCO3001\n\nJanssen Pharmaceuticals\nhttps://janssen.4gclinical.com\n\nSubject CZ100132003 has been randomized.\n\n    The following medication(s) has been assigned to the subject:\n\n    \n    \n        Medication No\n        Medication Type\n        Packaged Lot No\n        Expiration Date\n    \n    \n        \n            1056513\n            Icotrokinra 320mg / placebo\n            4393030\n            19-Jan-2027\n        \n    \n    \n\nSite Details\n\nLocation: CZE\n\nSite: DD5-CZ10013\n\nInvestigator: David Stepek\n\nSubject Details\n\nSubject: CZ100132003\n\nIRT Subject Status: Randomized\n\nCohort: Adult subjects (18 years or older)\n\n ADT-IR: No\n\n 3 or More Advanced Therapies: No\n\n Ustekinumab: No\n\n Only Oral 5-ASA Compounds: No\n \n Isolated Proctitis: No\n\nTransaction Date/Time (site local): 02-Jun-2026 08:19:11\n\nTransaction Date/Time (system local): 02-Jun-2026 06:19:11\n\nTransaction performed by: dstepek@vnbrno.cz\n\nIf you have questions about this notification, please contact 4G Clinical Support at http://support.4gclinical.com"
+}